Natasha is the President and Chief Executive Officer at Xanodyne Pharmaceuticals, Inc, an integrated and specialty drug company focused on pain management. She also served as the Chief Operating Officer.
With more than 25 years in the healthcare and pharmaceutical industry, Natasha brings extensive experience in business development, strategic and operational management, team leadership and top-and bottom-line growth strategies to ClearPoint’s Board of Directors. Prior to Xanodyne, Natasha held leadership positions at Cegedim Dendrite, Dendrite International, Parke-Davis/Pfizer and Parke-Davis/Warner-Lambert.
Natasha has a BSRN from Wagner College.
